Karyopharm Therapeutics Inc. (KPTI) has a MoatMap StockRank of 25/100 based on Quality (18/100), Value (51/100), and Momentum (47/100) factor scores. The current signal is SELL. Karyopharm Therapeutics, a small-cap healthcare company, does not align with any high-conviction macro inflection points and its business model as a biotech firm involves binary risks, which does not fit the fund's 'quality compounder' definition for a high-conviction position.